Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.46 and traded as low as $0.34. Elite Pharmaceuticals shares last traded at $0.3405, with a volume of 415,287 shares changing hands.

Elite Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.44 and a current ratio of 7.34. The company has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.46. The company has a market capitalization of $366.77 million, a price-to-earnings ratio of 11.35 and a beta of 0.40.

Elite Pharmaceuticals (OTCMKTS:ELTP) last posted its quarterly earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. The business had revenue of $31.59 million for the quarter. Elite Pharmaceuticals had a return on equity of 47.93% and a net margin of 30.98%.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.